Anti-angiogenic drugs that target vascular endothelial growth factors (VEGF)/VEGF receptor signaling have been widely used in the treatment of malignant tumors, such as metastatic renal cancer, lung cancer, breast cancer, etc. [6]. Here, VEGFA is linked to breast carcinoma.